SCHEMBL3020255

SCHEMBL3020255

Cc1cccc(C)c1-c1csc(N2CCC(S(=O)(=O)c3cccc(F)c3)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.45
NPC1 O15118 6/20 0.45
GPR6 P46095 1/20 0.42
SMN1; SMN2 Q16637 10/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 1/20 0.41
AR P10275 2/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
FAAH O00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002435 0.94 NPC1 (0.42) RAB9ANPC1GPR6SMN1; SMN2L3MBTL1
SCHEMBL3019012 0.90 SMN1; SMN2 (0.46) RAB9ANPC1GPR6SMN1; SMN2L3MBTL1
SCHEMBL3007141 0.90 SMN1; SMN2 (0.49) RAB9ANPC1SMN1; SMN2L3MBTL1USP2
SCHEMBL3013809 0.89 AR (0.44) RAB9ANPC1GPR6SMN1; SMN2L3MBTL1
SCHEMBL3012951 0.88 SMN1; SMN2 (0.51) RAB9ANPC1SMN1; SMN2MAPTMAPK1
SCHEMBL2997894 0.88 RAB9A (0.43) RAB9ANPC1SMN1; SMN2MAPTMAPK1
SCHEMBL3022723 0.87 RAB9A (0.47) RAB9ANPC1SMN1; SMN2L3MBTL1USP2
SCHEMBL3016070 0.87 CTSS (0.48) RAB9ANPC1SMN1; SMN2L3MBTL1AR
SCHEMBL3010240 0.87 RAB9A (0.47) RAB9ANPC1GPR6SMN1; SMN2L3MBTL1
SCHEMBL3021646 0.87 SMN1; SMN2 (0.53) RAB9ANPC1SMN1; SMN2L3MBTL1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885NPC1 15/4885GPR6 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.